{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:59:58Z","timestamp":1787320798639,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Medical treatment for acromegaly commonly involves receiving intramuscular or deep subcutaneous injections of somatostatin receptor ligands (SRLs) in most patients. In addition to side effects of treatment, acromegaly patients often still experience disease symptoms even when therapy is successful in controlling GH and IGF-1 levels. Symptoms and side effects can negatively impact patients\u2019 health-related quality of life. In this study, we examine the disease- and treatment-related burden associated with SRL injections as reported through the use of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ\n                    <jats:sup>\u00a9<\/jats:sup>\n                    ) and clinician-reported symptom severity through the Acromegaly Index of Severity (AIS). Patients included in this analysis were enrolled in a randomized phase 3 study, were biochemically-controlled (an IGF-1 &amp;lt; 1.3 \u00d7 the upper limit of normal [ULN] and average GH &amp;lt; 2.5 ng\/ml) and receiving SRL injections for \u22656 months with a stable dose of either long-acting octreotide or lanreotide monotherapy for \u22654 months. The sample (N = 91) was 65% female, 91% Caucasian, with a mean [standard deviation (SD)] age of 53 (\n                    <jats:xref>1<\/jats:xref>\n                    ) years. Two-thirds of patients reported that they still experience acromegaly symptoms; 82% of these said they experience symptoms all of the time. Three-fourths experienced gastrointestinal (GI) side effects after injections, and 77% experienced treatment-related injection site reactions (ISRs). Patients commonly reported that these interfered with their daily life, leisure, and work activities. Those with higher symptom severity, as measured by the AIS, scored significantly worse on several Acro-TSQ domains: Symptom Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction. Despite being biochemically controlled with injectable SRLs, most patients reported experiencing acromegaly symptoms that interfere with daily life, leisure, and work. GI side effects and ISRs were also common. This study highlights the significant disease burden that still persists for patients with acromegaly that have achieved biochemical control with the use of injectable SRLs.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2021.627711","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T12:22:26Z","timestamp":1615810946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands"],"prefix":"10.3389","volume":"12","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dreval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Ludlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asi","family":"Haviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossi","family":"Gilgun-Sherki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D.","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2007.10.002","article-title":"Acromegaly","volume":"37","author":"Ben-Shlomo","year":"2008","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocrine Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101309","DOI":"10.1016\/j.beem.2019.101309","article-title":"The burden of disease for pituitary patients","volume":"33","author":"Biermasz","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocrine Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036411","article-title":"Current therapies and mortality in acromegaly","volume":"8","author":"Galoiu","year":"2015","journal-title":"J Med Life"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1833","article-title":"A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update","volume":"105","author":"Giustina","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocrine Metab Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0372","article-title":"High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial","volume":"161","author":"Giustina","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00142","article-title":"High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study","volume":"102","author":"Giustina","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"B16","volume-title":"Sandostatin (octreotide acetate) injection [package insert]","year":"1998"},{"key":"B17","volume-title":"Somatuline depot (lanreotide) injection [package insert]","year":"2007"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2017-000570","article-title":"Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly","volume":"66","author":"Liu","year":"2018","journal-title":"J Invest Med: Off Publ Am Fed Clin Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0544-7","article-title":"Impact of treatment satisfaction on quality of life of patients with acromegaly","volume":"17","author":"Kepicoglu","year":"2014","journal-title":"Pituitary"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0853","article-title":"Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly","volume":"166","author":"Postma","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22683.1","article-title":"Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly","volume":"9","author":"Langlois","year":"2020","journal-title":"F1000Research"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1016\/S1530-891X(20)45228-0","article-title":"MPOWERED: Study design of a phase 3 head-to-head trial evaluating oral octreotide capsules versus injectable somatostatin analogs in patients with acromegaly","volume-title":"American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress","author":"Fleseriu","year":""},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00986-4","article-title":"Development of a novel patient-reported measure for acromegaly: the Acro-TSQ","volume":"22","author":"Fleseriu","year":"2019","journal-title":"Pituitary"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01038-y","article-title":"An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies","volume":"23","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"B27","article-title":"Evaluation of Acromegaly Symptoms from the newly developed AcromegalyTreatment Satisfaction Questionnaire (Acro-TSQ): a prospective patient-reported outcome study","volume-title":"99th Annual Meeting of the Endocrine Society (ENDO)","author":"Fleseriu","year":"2017"},{"key":"B28","article-title":"The ACRO-TSQ - A Novel Patient-Reported Tool to Assess Satisfaction with Acromegaly Treatment","volume-title":"The 8th International Congress of the GRS and IGF Society","author":"Fleseriu","year":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1210\/jcem.87.1.8153","article-title":"Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly","volume":"87","author":"Caron","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0478-0","article-title":"Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study","volume":"17","author":"Petersenn","year":"2014","journal-title":"Pituitary"},{"key":"B32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-2-13","article-title":"Acromegaly Quality of Life Questionnaire (AcroQoL)","volume":"2","author":"Badia","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res An Int J Qual Life Aspects Treatment Care Rehab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0207-x","article-title":"Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly","volume":"13","author":"Salvatori","year":"2010","journal-title":"Pituitary"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1371","article-title":"The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly","volume":"94","author":"Carmichael","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.627711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:01:36Z","timestamp":1671616896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.627711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":39,"alternative-id":["10.3389\/fendo.2021.627711"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.627711","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"article-number":"627711"}}